Merck Sharp + Dohme Corp.

Msd International Gmbh

Sebastian Schneider

Michelle R Machacek

Michael Hale Reutershan

Phieng Siliphaivanh

Shuhei Kawamura

Charles S Yeung

David James Witter

David L Sloman

Craig R Gibeau

Yingchun Ye

Ryan Quiroz

Michael D Altman

Jongwon Lim

Timothy J Henderson

Jean-Laurent Paparin

Houcine Rahali

Chunhui Huang

Sulagna Sanyal

David Annunziato Candito

Steven Mark Silverman

David J Witter

Murray Wan

Jonathan M E Hughes

Patrick S Fier

The present invention provides a compound of Formula (I) (I) and the pharmaceutically acceptable salts, esters, and prodrugs thereof, which are PRMT5 inhibitors. Also provided are methods of making compounds of Formula I, pharmaceutical compositions comprising compounds of Formula I, and methods of using these compounds to treat cancer, sickle cell, and hereditary persistence of foetal hemoglobin (HPFH) mutations.

PRMT5 inhibitors

The present invention provides a compound of Formula (I) and the pharmaceutically acceptable salts, esters, and prodrugs thereof, which are PRMT5 inhibitors. Also provided are methods of making compounds of Formula I, pharmaceutical compositions comprising compounds of Formula I, and methods of using these compounds to treat cancer, sickle cell, and hereditary persistence of foetal hemoglobin (HPFH) mutations.

The present invention provides a compound of Formula (I) Formula (I) or the pharmaceutically acceptable salts thereof, which are PRMT5 inhibitors.

The present invention provides a compound of Formula (I) or the pharmaceutically acceptable salts thereof, which are PRMT5 inhibitors.

Growing community of inventors

Boston, MA, United States of America

Sebastian Schneider